Analgesia aNd caNcer recUrrence Lung cAncer Resection

Completed

• Conditions: Recurrence Tumor; Thoracic Surgery; Opioid Use, Unspecified; Analgesia
• Interventions: Procedure: Peridural analgesia

• Registration Number: NCT04656769
• Lead Sponsor: University of Turin, Italy

Brief Summary

The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-17
• Primary Completion: 2020-04-01
• Study Completion: 2020-11-30
• Study First Submitted: 2020-11-30
• Study First Submitted QC: 2020-11-30
• Status Verified: 2020-12
• Study First Posted: 2020-12-07
• Last Update Submitted: 2020-12-18
• Last Update Posted: 2020-12-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 382

Inclusion Criteria

• Age ≥ 18 yrs
• Patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012

Exclusion Criteria

• Age<18aa
• Pregnancy
• Day hospital patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PERI group	Peridural analgesia	-

Primary Outcome Measures

Name	Time	Method
cumulative incidence of recurrence and the overall survival	5 years

Trial Locations

Locations (1)

AOU Città della Salute e della Scienza di Torino; 🇮🇹 Torino, Italy